Health & Biotech ASX Health Stocks: Painchek’s Europe patent accepted; and HeraMed signs deal with Telstra Health November 21, 2023 PainChek's European patent was accepted. HeraMed signs deal with Telstra, AdAlta announced interim Phase 1 results, Avita lowers 2023 guidance. ASX Health Stocks: 4DX jumps 15pc after FDA clearance; while AI-focused biotechs TrivarX and Artrya also gain November 20, 2023 4D Medical surged 15pc after a US FDA clearance. TrivarX moves rapidly to progress Phase 2 trial in depression. ScoPo’s Powerplays: Could ASX health stocks up for third week be a start of a Christmas rally? November 17, 2023 The ASX healthcare sector is up for the third week on the back of a strong rise in CSL (ASX:CSL)… ASX Health Stocks: Singular jumps 18pc after securing funds, Tax Office wipes smile off Pacific November 17, 2023 Singular Health jumps 18pc after securing funds, while Pacific Smiles Group says it may owe tax office some shortfalls. About… Why these ASX firms are shying away from the pot stock– Part Two November 17, 2023 They may be producing medicines using cannabis or psilocybin but these ASX stocks are shying away from the label 'pot… US FDA grants Argenica Orphan Drug designation to treat ‘devastating condition’ in newborns November 16, 2023 Argenica Therapeutics has achieved a key milestone, with the US Food and Drug Administration (FDA) granting orphan drug designation (ODD)… Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners November 16, 2023 Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in… Melodiol subsidiary HHI Australia delivers $1 million revenue in October November 15, 2023 Melodiol Global Health says it is delivering on its strategy to bring core operating subsidiaries to profitability with its fully… ASX Health Stocks: EBR stumbles 11pc after warning of FDA delay; Firebrick’s trial data shows ‘inaccuracies’ November 15, 2023 EBR Systems (ASX:EBR) tumbled 11% after saying that the FDA approval could be delayed due to more analysis. Why these ASX firms are shying away from the ‘pot stock’– Part One November 15, 2023 They may be producing medicines using cannabis or psilocybin but these ASX stocks are shying away from the label 'pot… Next» « Previous